Skip to main content
Premium Trial:

Request an Annual Quote

Miragen, Servier Extend microRNA Drug Alliance

Premium

NEW YORK (GenomeWeb) – Miragen Therapeutics this week announced that its research and development collaboration with France's Servier has been extended by two years to October 2016.

The companies first began working together in October 2011 under a three-year deal that gave Servier the rights to three of Miragen's preclinical microRNA inhibitor programs in cardiovascular disease in markets outside the US and Japan. These include ones focused on miR-208 for chronic heart failure, miR-15/195 for treating post-myocardial infarction remodeling, and a yet-to-be disclosed third program.

In exchange, Miragen received $45 million over the term of the arrangement, including upfront payments and milestones. Miragen also stands to receive royalties on product sales.

Financial terms of the extended partnership were not disclosed.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.